Tandem Diabetes Care Reports Third Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Tandem Diabetes (TNDM) Misses Q3 EPS by 28c, Revenues Beat; Offers FY18 Revenue Outlook Above Consensus
November 1, 2018 4:48 PM EDTTandem Diabetes (NASDAQ: TNDM) reported Q3 EPS of ($0.62), $0.28 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $46.26 million versus the consensus estimate of $41.83 million.
We delivered a record-setting quarter in terms of robust sales, improving gross margin and modest use... More
